Immunotherapy experience helps cancer patients with tumors to live 40 % longer | Cancer research
Cancer patients who were treated with pioneering immunotherapy, which genetically adjusts their own cells to wipe tumors that live 40 % longer, according to “exciting” and “pioneering” results from a global clinical trial.
The TD treatment for the car is a new form of immunotherapy, as the patient’s T cells are modified-a type of white blood cell-in a laboratory to target and kill cancer cells. The designed cells are then planted again in the bloodstream to fight the disease.
Treatment has already been successful in treating blood cancers. It now results from the first random experience governed in the world to treat T -car cells of the car in solid tumors indicating that the shift in controlling these cancers can also be.
Solid tumors represent about 90 % of all types of cancer, including breast, lung and pancreas cancer.
In the experiment that experts “teacher” praised by experts, patients with the intersection of the stomach or the advanced intestinal stomach (GEJ) who were treated with the treatment of T -car cells live on average about 40 % longer than patients who have received standard care.
The results were published in Lancet At the largest cancer conference in the world, the annual meeting of the American Association of Clinical Oncology (ASCO) was presented in Chicago.
“This is an exciting study that explains the first positive results of the experiment cells, the random experience of solid cancer,” said Dr. Karl Jun, a prominent expert in TT at the University of Pennsylvania, who did not participate in the experiment.
“The study showed that Satri-Cel Car provides great benefits for advanced stomach cancer patients who have failed in at least two previous lines of treatment. This represents a prominent sign in the field of car treatments against solid tumors.”
In the experiment, they were randomly chosen more than 100 patients in China with advanced stomach cancer or GEJ to receive either the treatment of the car of the car or one of the standard medicines for care. Patients who have received T -treatment T -Tel T with an average of 7.9 months after randomness, compared to 5.5 months through standard care.
Patients with immunotherapy also witnessed 3.3 months without cancer, compared to 1.8 months in the Standard Care Group.
The researchers, from the Beijing University Hospital and Institute in Beijing in Beijing, said that the treatment of the car’s T -cells “showed a significant statistical improvement in survival free of progress and a clinical meaning in general survival.” They added that the results indicate that the car’s T -cells “can represent a transformation” in the care, as they meet a decisive need that is not affected by some patients.
Dr. Jason Locke, ASCO expert and assistant professor at the University of Pittsburg, said the results are “exciting.” He added: “This is a very important publication” for the plant “that the cancer research community should gather to move forward towards improving the lives of patients [with] Solid tumors. “
A second study on Car T-Cell, led by the University of Pennsylvania, is to be presented at ASCO on Sunday, that the approach can also be used to treat brain tumors.
It is expected that the results of this experiment will appear that T Car T cells can reduce tumors in a beacon tumor, aggressive and rapid brain cancer, and help patients live longer.
CAR- Gmurial antigen receptors-TT therapy is done by engineering the patient’s cells T to recognize and destroy and destroy cancer cells.
T -cells are a type of white blood cells that can identify and destroy foreign cells, including cancer cells, but because cancer is able to evade immunity detection, they often miss their mark. The car is designed for the car to make it better in detecting cancer cells.
Chicago’s oncologists said they were increasingly optimistic that the treatment of T cells of cars could revolutionize the treatment of solid tumors, after great success with blood cancers.
“As for solid cancer, it is clear that there is now no interest now, but evidence that this treatment can benefit patients, which makes this an important new development that must be shared,” said Dr. John Hanin, of the Netherlands Cancer Institute, who will present a presentation on the treatment of T -cells at the ASCO meeting. “I think this [is] A new generation of treatment was not present for medical oncologists before. “
“It is encouraging” to see early signs that the treatment of TD cars can help patients with solid tumors. Elliot said that the treatment will need an experiment in larger numbers of patients before they are widely presented, but “it could be an important step forward for patients with limited treatment options.”